Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Chromatin run-on and sequencing maps the transcriptional regulatory landscape of glioblastoma multiforme.

Chu T, Rice EJ, Booth GT, Salamanca HH, Wang Z, Core LJ, Longo SL, Corona RJ, Chin LS, Lis JT, Kwak H, Danko CG.

Nat Genet. 2018 Nov;50(11):1553-1564. doi: 10.1038/s41588-018-0244-3. Epub 2018 Oct 22.

2.

Brain repair by hematopoietic growth factors in the subacute phase of traumatic brain injury.

Toshkezi G, Kyle M, Longo SL, Chin LS, Zhao LR.

J Neurosurg. 2018 Nov 1;129(5):1286-1294. doi: 10.3171/2017.7.JNS17878.

PMID:
29372883
3.

Development of a Function-Blocking Antibody Against Fibulin-3 as a Targeted Reagent for Glioblastoma.

Nandhu MS, Behera P, Bhaskaran V, Longo SL, Barrera-Arenas LM, Sengupta S, Rodriguez-Gil DJ, Chiocca EA, Viapiano MS.

Clin Cancer Res. 2018 Feb 15;24(4):821-833. doi: 10.1158/1078-0432.CCR-17-1628. Epub 2017 Nov 16.

4.

Current Practices of Awarding Graduation Honors within Doctor of Pharmacy Degree Programs.

DiPietro PA, Longo SL, Welch BE, Kennedy DR, Nemec EC.

Am J Pharm Educ. 2017 May;81(4):69. doi: 10.5688/ajpe81469.

5.

Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models.

Longo SL, Padalino DJ, McGillis S, Petersen K, Schirok H, Politz O, Canute GW, Post DE.

Invest New Drugs. 2012 Dec;30(6):2161-72. doi: 10.1007/s10637-011-9784-4. Epub 2011 Dec 29.

PMID:
22203214
6.

Development of an oncolytic herpes simplex virus using a tumor-specific HIF-responsive promoter.

Longo SL, Griffith C, Glass A, Shillitoe EJ, Post DE.

Cancer Gene Ther. 2011 Feb;18(2):123-34. doi: 10.1038/cgt.2010.62. Epub 2010 Oct 8.

7.

Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and antitumor efficacy.

Cherry T, Longo SL, Tovar-Spinoza Z, Post DE.

Gene Ther. 2010 Dec;17(12):1430-41. doi: 10.1038/gt.2010.100. Epub 2010 Jul 22.

8.

Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo.

Eller JL, Longo SL, Kyle MM, Bassano D, Hicklin DJ, Canute GW.

Neurosurgery. 2005;56(1):155-62; discussion 162.

PMID:
15617598
9.

Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.

Eller JL, Longo SL, Hicklin DJ, Canute GW.

Neurosurgery. 2002 Oct;51(4):1005-13; discussion 1013-4.

PMID:
12234411
10.

Apoptosis and survival in high-grade astrocytomas as related to tumor Fas (APO-1/CD95) expression.

Frankel B, Longo SL, Leach C, Canute GW, Ryken TC.

J Neurooncol. 2002 Aug;59(1):27-34.

PMID:
12222835
11.

Tumor Fas (APO-1/CD95) up-regulation results in increased apoptosis and survival times for rats with intracranial malignant gliomas.

Frankel B, Longo SL, Kyle M, Canute GW, Ryken TC.

Neurosurgery. 2001 Jul;49(1):168-75; discussion 175-6.

PMID:
11440439
12.
13.

Human astrocytomas co-expressing Fas and Fas ligand also produce TGFbeta2 and Bcl-2.

Frankel B, Longo SL, Ryken TC.

J Neurooncol. 1999;44(3):205-12.

PMID:
10720200
14.

Co-expression of Fas and Fas ligand in human non-astrocytic glial tumors.

Frankel B, Longo SL, Ryken TC.

Acta Neuropathol. 1999 Oct;98(4):363-6.

PMID:
10502041
15.

Antisense oligonucleotide-induced inhibition of adrenocorticotropic hormone release from cultured human corticotrophs.

Frankel B, Longo SL, Rodziewicz GS, Hodge CJ Jr.

J Neurosurg. 1999 Aug;91(2):261-7.

PMID:
10433314
16.
17.

An assay for quantifying DNA double-strand break repair that is suitable for small numbers of unlabeled cells.

Longo JA, Nevaldine B, Longo SL, Winfield JA, Hahn PJ.

Radiat Res. 1997 Jan;147(1):35-40.

PMID:
8989367
18.

Hydroxyurea accelerates the loss of epidermal growth factor receptor genes amplified as double-minute chromosomes in human glioblastoma multiforme.

Canute GW, Longo SL, Longo JA, Winfield JA, Nevaldine BH, Hahn PJ.

Neurosurgery. 1996 Nov;39(5):976-83.

PMID:
8905754

Supplemental Content

Loading ...
Support Center